Monitor the next quarterly report for updates on trial enrollment progress and any changes in funding strategy, as the $944,820 expense represents a significant commitment for a company with a $9M market cap.
Price Chart
Executive Summary
Nexalin Technology entered into a $944,820 agreement with Lindus Health to conduct a pivotal clinical trial for its HALO Clarity device, aimed at supporting a De Novo FDA submission for moderate-to-severe insomnia. The trial is expected to begin enrollment in Q2 2026.
Key Financial Metrics
Key Facts
- Nexalin Technology entered into a Scope of Work (SOW) with Lindus Health Limited on April 17, 2026.
- The SOW governs the pivotal clinical trial for the HALO Clarity device, with direct fees totaling approximately $944,820 plus pass-through expenses.
- The trial is a 160-participant, randomized, triple-blinded, sham-controlled study designed to support a De Novo FDA submission.
- Patient enrollment is expected to begin in Q2 2026.
- Lindus Health will manage full-scope trial execution, including protocol finalization, regulatory submissions, patient identification, data oversight, biostatistics, and medical writing.
Financial Impact
The company will pay approximately $944,820 in direct fees plus pass-through expenses to Lindus Health for the pivotal clinical trial.
Risk Factors
- The trial may face delays or cost overruns due to change orders for protocol amendments, additional participants, or extended study duration.
- The company's ability to secure adequate funding for the trial and future regulatory submissions is uncertain.
- The trial may not produce favorable results, which could impact the company's ability to obtain FDA clearance or approval.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001829126-26-003765 |
| Document: nexalintec_ex99-1.htm | 0001829126-26-003765 |
| Document: 0001829126-26-003765-index-headers.html | 0001829126-26-003765 |
| Document: 0001829126-26-003765-index.html | 0001829126-26-003765 |
| Document: 0001829126-26-003765.txt | 0001829126-26-003765 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | EFFECT | $2.35 | awaiting T+20 | — | $1.71 (+27.23%) |
Oct 8, 2026 18d ago | S-1/A | $3.63 | awaiting T+20 | — | $1.71 (+52.89%) |
Oct 1, 2026 25d ago | 8-K | $5.73 | awaiting T+20 | — | $1.71 (−70.16%) |
Oct 1, 2026 25d ago | 8-K | $5.73 | awaiting T+20 | — | $1.71 (−70.16%) |
Sep 2, 2026 7w ago | 8-K | $5.36 $4.28 | ▼ −20.15% | ▼ −19.03% | $1.71 (−68.10%) |
Aug 27, 2026 8w ago | 8-K | $0.2548 $0.1463 | ▼ −42.57% | ▼ −42.60% | $1.71 (+571.11%) |
Aug 17, 2026 10w ago | 8-K | $0.3400 $0.1617 | ▲ +52.45% | ▲ +50.47% | $1.71 (−402.94%) |
Jun 10, 2026 19w ago | Press Release | $0.4590 $0.4607 | ▲ +0.37% | ▼ −3.70% | $1.71 (+272.55%) |
May 19, 2026 22w ago | 8-K | $0.3350 $0.3680 | ▲ +9.85% | ▲ +9.11% | $1.71 (+410.45%) |
May 19, 2026 22w ago | Press Release | $0.3210 $0.3930 | ▲ +22.43% | ▲ +21.44% | $1.71 (+432.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers